iCAD (ICAD) 17th Annual LD Micro Main Event Conference summary

Market opportunity and industry trends

• Only 37% of US mammography clinics use AI, with significant global expansion potential; current reach is about 4,000 customers in 50 countries, reading 8 million mammograms annually.

• Strategic 20-year partnership with Google Health aims to develop advanced algorithms and expand market presence.

• US market share is about 15–18%, with room to grow as 63% of clinics do not use AI; half of the AI market is held by a major competitor bundling with hardware.

• New cloud solution launched in Q1 2024, enabling rapid onboarding and expansion into new markets.

• Large untapped international markets represent an additional 42 million women.

Business model transformation and financial performance

• Transitioned from perpetual license to subscription and cloud-based SaaS, with recurring revenue now 46% of GAAP revenue.

• Customer retention exceeds 93%, and Net Promoter Score is 90, indicating high satisfaction.

• Divested non-synergistic business and right-sized operations, improving cash position and reducing cash burn.

• Strong gross margins and a healthy cash position; no need for additional funding to execute current initiatives.

• Q2 cloud deals added $1.2 million to billings backlog; 10 customers make up 25% of revenue.

Technology and product innovation

• Four key AI solutions: cancer detection, breast density scoring, risk prediction (1–2 years ahead), and heart health assessment.

• Detection algorithm is twice as accurate as radiologists without AI, with 8% higher sensitivity and 7% lower recall rate.

• AI reduces radiologist reading time by 52%, critical as 3D mammography increases image volume.

• Breast density and detection algorithms are globally cleared; risk and heart health algorithms are progressing through FDA.

• Fourth-generation AI, co-developed with Duke University, is built on a new neural network.